

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **C4BPB RABBIT PAB**

Cat.#: S212150

**Product Name:** Anti-C4BPB Rabbit Polyclonal Antibody

Synonyms: C4BP

UNIPROT ID: P20851 (Gene Accession - BC005378)

**Background:** This gene encodes a member of a superfamily of proteins composed predominantly of tandemly arrayed short consensus repeats of approximately 60 amino acids. A single, unique beta-chain encoded by this gene assembles with seven identical alpha-chains into the predominant isoform of C4b-binding protein, a multimeric protein that controls activation of the complement cascade through the classical pathway. C4b-binding protein has a regulatory role in the coagulation system also, mediated through the beta-chain binding of protein S, a vitamin K-dependent protein that serves as a cofactor of activated protein C. The genes encoding both alpha and beta chains are located adjacent to each other on human chromosome 1 in the regulator of complement activation gene cluster. Alternative splicing gives rise to multiple

**Immunogen:** Fusion protein of human C4BPB

**Applications:** ELISA, IHC

**Recommended Dilutions:** IHC: 30-150; ELISA: 5000-10000

Host Species: Rabbit

transcript variants.

**Clonality:** Rabbit Polyclonal

**Isotype:** Immunogen-specific rabbit IgG **Purification:** Antigen affinity purification


Species Reactivity: Human

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40%


glycerol

Research Areas: Immunology

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 212150 (C4BPB Antibody) at a dilution of 1/35 (Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 212150(Anti-C4BPB Antibody) at dilution 1/35.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010